Biomea Fusion Appoints Julianne Averill to its Board of Directors

Core Viewpoint - Biomea Fusion, Inc. has appointed Julianne Averill to its Board of Directors, effective July 22, 2025, succeeding Bihua Chen, who has served for over four years [1][2]. Group 1: Appointment Details - Julianne Averill brings extensive financial, operational, and strategic expertise in life sciences and digital health, which will benefit Biomea's mission to transform diabetes and obesity care [2]. - Averill has over two decades of experience in high-growth life sciences and digital health companies, currently serving as Managing Director at Danforth Advisors [2]. - She has been involved in transactions and strategic initiatives exceeding $10 billion in aggregate value [2]. Group 2: Background of Julianne Averill - Averill holds a B.S. in Business Administration and an M.S. in Accountancy from California State University [3]. - She is a licensed CPA in California and holds certifications from the Society of Human Resources and the National Association of Corporate Directors [3]. Group 3: Company Overview - Biomea Fusion is focused on developing oral small molecules, icovamenib and BMF-650, aimed at improving the lives of patients with diabetes, obesity, and metabolic diseases [4].